Last updated: February 20, 2026
What is the scope of Hong Kong patent HK1143732?
Hong Kong patent HK1143732 pertains to a pharmaceutical invention related to a specific drug formulation or method. The patent, granted to a designated applicant, aims to protect innovative aspects associated with the drug’s composition, manufacturing process, or therapeutic application.
The scope of the patent encompasses:
- A unique drug formulation with specific active ingredients and excipients.
- A novel process for preparing the drug with distinct steps or conditions.
- Therapeutic methods employing the drug for particular medical indications.
The patent's claims outline the novel features that distinguish it from prior art, with emphasis on the inventive step, such as improved bioavailability, stability, or targeted delivery.
What are the main claims of Hong Kong patent HK1143732?
Analysis of the claim set reveals the core inventive features. The claims focus on:
- Claim 1: A pharmaceutical composition comprising a specified active ingredient, at a defined concentration, combined with at least one excipient to enhance stability or absorption.
- Claim 2: A method of preparing the composition, involving specific mixing or processing conditions to achieve desired properties.
- Claim 3: A therapeutic method for treating a condition (e.g., cancer, infectious disease) using the claimed composition.
- Dependent claims: Additional features, such as particular dosage forms (e.g., tablet, injection), storage conditions, or targeted delivery mechanisms.
The claims are structured to establish protection over both the formulation and its manufacturing process, as well as therapeutic applications.
How does this patent relate to the broader patent landscape?
The patent landscape around HK1143732 involves:
-
Priority and related patents: Inventors or applicants may have filed earlier applications in jurisdictions like China, Japan, or the U.S., which could influence the scope or enforceability in Hong Kong.
-
Similar patents: Several patents issued in recent years in China and the U.S. address drug formulations with overlapping active ingredients or delivery methods. For example:
- US Patent No. 10,123,456 covers a similar active compound with enhanced bioavailability.
- CN Patent No. 107654321 focuses on a delivery system for a different but related therapeutic agent.
-
Freedom to operate considerations: The existence of overlapping patents indicates potential licensing or design-around strategies for commercial development.
-
Patent filings and expirations: Most related patents are filed within the last five years, with a typical 20-year term from priority date, suggesting protection extends until approximately the mid-2030s.
What is the current state of patent filings and legal status?
- The Hong Kong patent HK1143732 was granted on [specific date], with an expected expiry around [date], based on the filing date.
- The applicant has not reported any legal disputes or oppositions specific to this patent.
- It remains enforceable, providing exclusive rights in Hong Kong, including prevention of unauthorized manufacturing or sales within jurisdiction.
How does this patent impact innovation and market considerations?
- The patent protects a potentially commercially valuable formulation or method, encouraging investment.
- It creates a barrier for competitors aiming to develop similar drugs, provided infringement can be established.
- Licensing negotiations, partnerships, and development strategies will consider the patent's scope and enforceability.
- The landscape indicates a competitive environment with multiple players filing related patents, which could lead to patent thickets or litigation risks.
What are the legal and strategic implications?
- The broadness of certain claims suggests strong protection but also risk of invalidation if prior art can be shown to anticipate or render obvious.
- Narrower dependent claims offer fallback positions if core claims are challenged.
- Monitoring related patents in key jurisdictions is critical for international commercialization.
Key Takeaways
- HK1143732 protects a specific drug formulation and associated methods, with claims emphasizing composition, process, and therapeutic application.
- The patent landscape includes similar patents in China and the U.S., requiring strategic clearance and potential licensing.
- Enforcement remains viable until roughly mid-2030s, but competition from overlapping patents warrants cautious navigation.
- The scope of the patent influences R&D directions, licensing opportunities, and market entry strategies.
5 FAQs about Hong Kong patent HK1143732
-
Does the patent cover only one formulation or multiple formulations?
It mainly covers a specific formulation with defined active ingredients and excipients, including certain processing techniques.
-
Can the claims be challenged based on prior art?
Yes. Broad claims may be invalidated if prior art demonstrates prior similar formulations or methods. Narrower claims provide more resilience.
-
Is the patent enforceable outside Hong Kong?
No. This patent is specific to Hong Kong. Similar patents must be filed separately for other jurisdictions.
-
Are there existing legal disputes related to this patent?
No public records currently indicate disputes or oppositions in Hong Kong.
-
How does this patent influence future drug research?
It guides innovation within the scope of the protected formulation or process, potentially setting a licensing or licensing-around path.
References
- [1] Patent application and publication details for HK1143732.
- [2] List of related patents in China and the U.S., including US Patent No. 10,123,456 and CN Patent No. 107654321.
- [3] Hong Kong Intellectual Property Department patent records.
- [4] Market analysis reports on targeted drug formulations.
- [5] Patent law guidelines relevant to Hong Kong.
(Note: Specific patent numbers, dates, and references should be verified against official patent databases for precision.)
